Form 4: STAAR Surgical Director Wei Jiang Receives Annual Equity Grant

STAAR Surgical Co. Director Wei Jiang was granted 10,683 restricted stock units as part of the company's annual non-employee director equity compensation program.

Summary

• Wei Jiang, a Director of STAAR Surgical Co. (STAA), received an equity award on June 18, 2025.
• The award consists of 10,683 Restricted Stock Units (RSUs), which represent the right to receive one share of the Corporation's common stock upon vesting.
• These RSUs were granted at a price of $0, consistent with typical equity compensation awards.
• The equity awards are part of the Corporation's annual non-employee director equity compensation program for the 2025-2026 term.
• The RSUs are scheduled to vest in full on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders.
• Following this transaction, Wei Jiang beneficially owns 10,683 derivative securities (RSUs) directly.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning interests but not a significant market-moving event. It reflects standard corporate governance practices.

Positives

• The grant of Restricted Stock Units to Director Wei Jiang aligns his interests with those of the shareholders, as the value of the compensation is directly tied to the company's stock performance.
• This transaction is a standard component of non-employee director compensation, indicating a structured and routine approach to corporate governance and incentivization.

Future Outlook

The 10,683 Restricted Stock Units granted to Director Wei Jiang are scheduled to vest in full on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders, indicating a future milestone for the equity compensation.

Management Comments

• "This Form 4 reflects the equity awards granted to the Reporting Person on June 18, 2025, pursuant to the Corporation's annual non-employee director equity compensation program for the 2025-2026 term."

Industry Context

The grant of Restricted Stock Units to a non-employee director is a common practice across publicly traded companies, particularly in the medical device and ophthalmic industry where STAAR Surgical operates. This method of compensation is widely used to attract and retain qualified board members by aligning their financial interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of equity awards, specifically Restricted Stock Units, to non-employee directors is a standard compensation practice in the U.S. corporate landscape, including companies comparable to STAAR Surgical in the medical technology sector.
• While specific comparable companies or projects are not detailed in this filing, the structure of the RSU grant (zero exercise price, time-based vesting) is consistent with typical non-employee director compensation packages designed to incentivize long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The grant of 10,683 Restricted Stock Units to Wei Jiang, a director of STAAR Surgical Co., constitutes a related party transaction as it involves compensation from the company to an insider. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.

Next Steps

• Vesting of the 10,683 Restricted Stock Units on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders.

Key Dates

Keywords

STAAR Surgical, STAA, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Director Compensation, Corporate Governance, SEC Filing